Lantheus appoints new hires, including former Bristol-Myers exec
Lantheus Medical Imaging has made a series of new hires to support its core business functions including regulatory affairs and quality operations.
Lantheus appointments include:
• Mary Taylor as vice president (VP) of regulatory affairs;
• Ildia González Ojeda as senior director of quality operations; and
• Jeffrey Young as global controller.
Additionally, the North Billrica, Mass.-based company has hired Shelley Gullotti as director of leadership and organization development; Stephen Schmitz as medical director, pharmacovigilence; Peter Fipphen as director of tax; and Matthew Kowalsky as assistant general counsel.
Taylor brings more than 25 years of experience in the pharmaceutical regulatory industry to her new role. She joins Lantheus after serving as VP, regulatory affairs for both Tolerx and CuraGen, where she led all regulatory affairs activities company-wide.
Ojeda brings more than 15 years of experience to her new role as senior director of quality operations. She joins Lantheus from Bristol-Myers Squibb, where she served as quality control/quality assurance director and was responsible for all activities related to the development of quality assurance guides, procedures and systems, product reviews and GMP regulatory inspections of the company's Mayagüez, Puerto Rico location.
Young joins Lantheus as global controller from Critical Therapeutics, a biopharmaceutical company focused on products that treat respiratory, inflammatory and critical care diseases, where he served as the chief accounting officer, VP of finance and treasurer. Before joining Critical Therapeutics, Young spent several years at PerkinElmer, most recently as a senior manager within its controllership organization.
Lantheus appointments include:
• Mary Taylor as vice president (VP) of regulatory affairs;
• Ildia González Ojeda as senior director of quality operations; and
• Jeffrey Young as global controller.
Additionally, the North Billrica, Mass.-based company has hired Shelley Gullotti as director of leadership and organization development; Stephen Schmitz as medical director, pharmacovigilence; Peter Fipphen as director of tax; and Matthew Kowalsky as assistant general counsel.
Taylor brings more than 25 years of experience in the pharmaceutical regulatory industry to her new role. She joins Lantheus after serving as VP, regulatory affairs for both Tolerx and CuraGen, where she led all regulatory affairs activities company-wide.
Ojeda brings more than 15 years of experience to her new role as senior director of quality operations. She joins Lantheus from Bristol-Myers Squibb, where she served as quality control/quality assurance director and was responsible for all activities related to the development of quality assurance guides, procedures and systems, product reviews and GMP regulatory inspections of the company's Mayagüez, Puerto Rico location.
Young joins Lantheus as global controller from Critical Therapeutics, a biopharmaceutical company focused on products that treat respiratory, inflammatory and critical care diseases, where he served as the chief accounting officer, VP of finance and treasurer. Before joining Critical Therapeutics, Young spent several years at PerkinElmer, most recently as a senior manager within its controllership organization.